Chugai Pharmaceutical Co. Ltd., of Tokyo, said data from hemophilia A patients in a phase I study of bispecific antibody emicizumab, published in The New England Journal of Medicine, demonstrated a clinically acceptable safety profile and a potential benefit for preventing bleeding in patients, both with and without factor VIII inhibitors. Emicizumab is a once-weekly subcutaneous injection and has be designated a breakthrough therapy by the FDA. It’s currently in a phase III study in collaboration with Basel, Switzerland-based Roche AG.